Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

16.39 +0.49 (+3.11%)

Streaming Delayed Price Updated: 12:49 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

19 20 Next >

NeurAxis: Should You Buy This IPO? ↗

February 08, 2023

As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.

Via Talk Markets

NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution ↗

February 06, 2023

As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.

Via Talk Markets

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

February 03, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged ↗

February 02, 2023

Via Benzinga

Current Report: Takeda Pharmaceutical (TAK) ↗

January 23, 2023

In the past year, Takeda’s share price increased by $1.73, or about 12%.

Via Talk Markets

HUTCHMED Out Licenses Fruquintinib To Takeda Outside China ↗

January 23, 2023

Via Benzinga

A Bullish Sign Appears On Takeda Pharmaceutical's Chart ↗

December 28, 2022

Via Benzinga

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

February 02, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 Sorry Dividend Stocks to Sell in February Before It’s Too Late ↗

January 30, 2023

These dividend stocks to sell have weak underlying fundamentals, offering little upside potential ahead for investors.

Via InvestorPlace

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce ↗

January 24, 2023

Via Benzinga

Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B ↗

December 13, 2022

Via Benzinga

Takeda's Dengue Vaccine Candidate Under FDA Priority Review ↗

November 23, 2022

Via Benzinga

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

January 23, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

January 23, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Named Global Top Employer for Sixth Consecutive Year

January 16, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices ↗

January 14, 2023

Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...

Via Talk Markets

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

January 11, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study ↗

January 09, 2023

Via Benzinga

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

January 09, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

January 05, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies ↗

December 14, 2022

Via Benzinga

Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

December 13, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases

December 09, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union

December 08, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

December 06, 2022

From Singapore Economic Development Board (EDB)A*STAR

Via ACN Newswire

Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities? ↗

November 30, 2022

Tech layoffs are in the news, but life sciences companies seem to be doing better.

Via The Motley Fool

Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease ↗

November 29, 2022

The company says it plans soon to present Phase 2 results and its Phase 3 study design.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.